Analysts Estimates and Ratings: Abbott Laboratories (NYSE:ABT)
- Author: Zachary Reyes Mar 15, 2017,
Mar 15, 2017, 20:22
A number of other institutional investors have also added to or reduced their stakes in ABT.
Abbott Laboratories (NYSE:ABT)'s growth estimate is 4.9 percent for the current quarter. Ltd. now owns 2,643,491 shares of the healthcare product maker's stock valued at $101,518,000 after buying an additional 2,492,853 shares during the period. JinkoSolar Holding Co., Ltd. (NYSE:JKS) has declined 17.48% since August 5, 2016 and is downtrending. The Manufacturers Life Insurance Company bought a new stake in Abbott Laboratories during the third quarter valued at $121,629,000. The average numbers of shares are traded in a security per day, during the recent 3-month period. Williams Jones & Associates LLC raised its position in Abbott Laboratories by 101.5% in the second quarter. Abbott Laboratories (NYSE:ABT), at its latest closing price of $44.80, it has a price-to-book ratio of 3.27, compared to an industry average at 4.08.
Hedge funds have recently made changes to their positions in the company.
Abbott Laboratories (NYSE:ABT) ended its day at $44.80 with the rising stream of -1.60% and its total traded volume was 7.5 million shares less than the average volume. The company has market cap of $77.35 billion. The share price has moved backward from its 20 days moving average -0.48% and positively from its 50 days moving average 5.28%.
The 52-week high of the share price is -21.88% and 52-week low of the share price is 15.97%.
Abbott Laboratories (NYSE:ABT) has outperformed YTD, increasing 19% versus the S&P 500's 6% and the S&P E&S's 14%.
A current consensus EPS estimate for next quarter is at $0.60 and 3 month ago EPS forecast was $0.61. The business had revenue of $5.33 billion for the quarter, compared to analysts' expectations of $5.41 billion. A ROI of 6.70% for the company evaluates and compares the efficiency of the various numbers of investments relative to the cost of investments. On the other hand, in the September 2017 quarter the company recorded a net $5.3B revenue with earnings per share of $0.59. This contrasts with this year Q4 current estimates trend of $0.43 while for one month was for $0.43. Jensen Invest stated it has 136,787 shares or 0.08% of all its holdings. It has a dividend yield of 2.33%. The ex-dividend date is Tuesday, April 11th. Abbott Laboratories P/E (price to earnings) ratio is 63.85 and Forward P/E ratio of 16.62. Sure, the percentage is discouraging but better times are ahead as looking out over a next 5-year period, analysts expect the company to see its earnings go up by 11.24%, annually. If you are viewing this piece on another publication, it was stolen and reposted in violation of US and worldwide copyright legislation. Jefferies Group LLC restated a buy rating and set a $46.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, December 20th.
08/09/2016 - Abbott Laboratories had its "buy" rating reiterated by analysts at BTIG Research. On Friday, January 29 the stock rating was maintained by RBC Capital Markets with "Outperform". Abbott Laboratories presently has an average rating of "Buy" and an average price target of $47.92. (NYSE:JKS), 4 have Buy rating, 0 Sell and 1 Hold. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company.
When it comes to the Analysis of a Stock, Price Target plays a vital role.
On 1/31/2017 Heather L Mason, Insider, sold 35,700 with an average share price of $40.77 per share and the total transaction amounting to $1,455,489.00. The company's outstanding shares are 404.71 Million. Blaser Brian J bought 15,580 shares worth $599,120.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) [Trend Analysis] shows fluctuation in active trade, on Friday shares slightly down -0.67% to $126.55. The disclosure for this sale can be found here.
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.